1887
  1. Home
  2. Eurosurveillance
  3. Volume 24, Issue 20, 16/May/2019
  4. Article
Research Open Access
Like 0
Download

Abstract

Background

Antimicrobial resistance is widely considered an urgent global health issue due to associated mortality and disability, societal and healthcare costs.

Aim

To estimate the past, current and projected future proportion of infections resistant to treatment for eight priority antibiotic-bacterium combinations from 2000 to 2030 for 52 countries.

Methods

We collated data from a variety of sources including ResistanceMap and World Bank. Feature selection algorithms and multiple imputation were used to produce a complete historical dataset. Forecasts were derived from an ensemble of three models: exponential smoothing, linear regression and random forest. The latter two were informed by projections of antibiotic consumption, out-of-pocket medical spending, populations aged 64 years and older and under 15 years and real gross domestic product. We incorporated three types of uncertainty, producing 150 estimates for each country-antibiotic-bacterium-year.

Results

Average resistance proportions across antibiotic-bacterium combinations could grow moderately from 17% to 18% within the Organisation for Economic Co-operation and Development (OECD; growth in 64% of uncertainty sets), from 18% to 19% in the European Union/European Economic Area (EU/EEA; growth in 87% of uncertainty sets) and from 29% to 31% in Group of Twenty (G20) countries (growth in 62% of uncertainty sets) between 2015 and 2030. There is broad heterogeneity in levels and rates of change across countries and antibiotic-bacterium combinations from 2000 to 2030.

Conclusion

If current trends continue, resistance proportions are projected to marginally increase in the coming years. The estimates indicate there is significant heterogeneity in resistance proportions across countries and antibiotic-bacterium combinations.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2019.24.20.1800445
2019-05-16
2024-11-29
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2019.24.20.1800445
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/24/20/eurosurv-24-20-4.html?itemId=/content/10.2807/1560-7917.ES.2019.24.20.1800445&mimeType=html&fmt=ahah

References

  1. Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, et al. Burden of AMR Collaborative Group. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56-66.  https://doi.org/10.1016/S1473-3099(18)30605-4  PMID: 30409683 
  2. European Centre for Disease Prevention and Control (ECDC) and European Medicines Agency. (EMEA) Joint Working Group. ECDC/ EMEA Joint Technical Report: The bacterial challenge: Time to react [Internet]. Stockholm: ECDC & EMEA; 2009. Available from: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf
  3. Centers for Disease Control and Prevention (CDC). Antibiotic Resistance Threats in the United States, 2013. Atlanta: CDC; 2013. Available from: https://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf
  4. O’Neill J. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. London: HM Government; 2016. Available from: https://amr-review.org/sites/default/files/160525_Final paper_with cover.pdf.
  5. World Bank. Drug-Resistant Infections: A Threat to Our Economic Future. Washington, DC: World Bank; 2017. Available from: http://documents.worldbank.org/curated/en/323311493396993758/pdf/114679-REVISED-v2-Drug-Resistant-Infections-Final-Report.pdf
  6. de Kraker MEA, Stewardson AJ, Harbarth S. Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050? PLoS Med. 2016;13(11):e1002184.  https://doi.org/10.1371/journal.pmed.1002184  PMID: 27898664 
  7. Costello JC, Heiser LM, Georgii E, Gönen M, Menden MP, Wang NJ, et al. NCI DREAM Community. A community effort to assess and improve drug sensitivity prediction algorithms. Nat Biotechnol. 2014;32(12):1202-12.  https://doi.org/10.1038/nbt.2877  PMID: 24880487 
  8. Dieleman JL, Campbell M, Chapin A, Eldrenkamp E, Fan VY, Haakenstad A, et al. Global Burden of Disease Health Financing Collaborator Network. Future and potential spending on health 2015-40: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries. Lancet. 2017;389(10083):2005-30.  https://doi.org/10.1016/S0140-6736(17)30873-5  PMID: 28433260 
  9. Kontis V, Bennett JE, Mathers CD, Li G, Foreman K, Ezzati M. Future life expectancy in 35 industrialised countries: projections with a Bayesian model ensemble. Lancet. 2017;389(10076):1323-35.  https://doi.org/10.1016/S0140-6736(16)32381-9  PMID: 28236464 
  10. Organisation for Economic Co-operation and Development (OECD). Antimicrobial Resistance in G7 Countries and Beyond: Economic Issues, Policies and Options for Action. Paris: OECD; 2015. Available from: http://www.oecd.org/els/health-systems/Antimicrobial-Resistance-in-G7-Countries-and-Beyond.pdf
  11. World Health Organization (WHO). Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. Geneva: WHO; 2017. Available from: http://www.who.int/medicines/areas/rational_use/PPLreport_2017_09_19.pdf?ua=1
  12. Center for Disease Dynamics E and P (CDDEP). ResistanceMap. CDDEP: Washington, DC; [cited 2018 Jul 24]. Available from: https://resistancemap.cddep.org/index.php
  13. Byarugaba DK. A view on antimicrobial resistance in developing countries and responsible risk factors. Int J Antimicrob Agents. 2004;24(2):105-10.  https://doi.org/10.1016/j.ijantimicag.2004.02.015  PMID: 15288307 
  14. Harbarth S, Samore MH. Antimicrobial resistance determinants and future control. Emerg Infect Dis. 2005;11(6):794-801.  https://doi.org/10.3201/eid1106.050167  PMID: 15963271 
  15. Chatterjee A, Modarai M, Naylor NR, Boyd SE, Atun R, Barlow J, et al. Quantifying drivers of antibiotic resistance in humans: a systematic review. Lancet Infect Dis. 2018;18(12):e368-78.  https://doi.org/10.1016/S1473-3099(18)30296-2  PMID: 30172580 
  16. Holmes AH, Moore LSP, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet. 2016;387(10014):176-87.  https://doi.org/10.1016/S0140-6736(15)00473-0  PMID: 26603922 
  17. Honaker J, King G, Blackwell M, Amelia II. A Program for Missing Data. J Stat Softw. 2011;45(7):1-47.  https://doi.org/10.18637/jss.v045.i07 
  18. Liu JX, Goryakin Y, Maeda A, Bruckner T, Scheffler R. Global Health Workforce Labor Market Projections for 2030. Hum Resour Health. 2017;15(1):11.  https://doi.org/10.1186/s12960-017-0187-2  PMID: 28159017 
  19. United Nations (UN). Department of Economic and Social Affairs Population Division. World Population Prospects: The 2017 Revision, Volume I: Comprehensive Tables. New York: UN; 2017. Available from: https://esa.un.org/unpd/wpp/Publications/Files/WPP2017_Volume-I_Comprehensive-Tables.pdf
  20. United States Department of Agriculture (USDA) Economic Research Service. International Macroeconomic Data Set. Washington, DC: USDA; [cited 2018 Jul 24]. Available from: https://www.ers.usda.gov/data-products/international-macroeconomic-data-set/
  21. Baker RE, Peña J-M, Jayamohan J, Jérusalem A. Mechanistic models versus machine learning, a fight worth fighting for the biological community? Biol Lett. 2018;14(5):20170660.  https://doi.org/10.1098/rsbl.2017.0660  PMID: 29769297 
  22. Kandula S, Yamana T, Pei S, Yang W, Morita H, Shaman J. Evaluation of mechanistic and statistical methods in forecasting influenza-like illness. J R Soc Interface. 2018;15(144):20180174.  https://doi.org/10.1098/rsif.2018.0174  PMID: 30045889 
  23. Birkegård AC, Halasa T, Toft N, Folkesson A, Græsbøll K. Send more data: a systematic review of mathematical models of antimicrobial resistance. Antimicrob Resist Infect Control. 2018;7(1):117.  https://doi.org/10.1186/s13756-018-0406-1  PMID: 30288257 
  24. Hyndman RJ, Athanasopoulos G. Forecasting : principles and practice. OTexts. Online book. Montash University, Australia: Forecasting; 2018. Available from: https://otexts.com/fpp2/
  25. Kuhn M, Johnson K. Applied Predictive Modeling. New York: Springer; 2016. Available from: https://link.springer.com/content/pdf/10.1007/978-1-4614-6849-3.pdf
  26. Klein EY, Van Boeckel TP, Martinez EM, Pant S, Gandra S, Levin SA, et al. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci USA. 2018;115(15):E3463-70.  https://doi.org/10.1073/pnas.1717295115  PMID: 29581252 
  27. European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe 2016. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2017. Available from: https://ecdc.europa.eu/sites/portal/files/documents/AMR-surveillance-Europe-2016.pdf
  28. Dimopoulos G, Kollef MH, Cohen J. In 2035, will all bacteria be multiresistant? Yes. Intensive Care Med. 2016;42(12):2014-6.  PMID: 27091441 
  29. Barbier F, Lipman J, Bonten MJM. In 2035, will all bacteria be multidrug-resistant? No. Intensive Care Med. 2016;42(12):2017-20.  PMID: 27091442 
  30. Laupland KB, Ruppé E, Harbarth S. In 2035, will all bacteria be multidrug resistant? We are not sure. Intensive Care Med. 2016;42(12):2021-3.  https://doi.org/10.1007/s00134-016-4343-2  PMID: 27091440 
  31. Wernli D, Jørgensen PS, Harbarth S, Carroll SP, Laxminarayan R, Levrat N, et al. Antimicrobial resistance: The complex challenge of measurement to inform policy and the public. PLoS Med. 2017;14(8):e1002378.  https://doi.org/10.1371/journal.pmed.1002378  PMID: 28817562 
Resistance proportions for eight priority antibiotic-bacterium combinations in OECD, EU/EEA and G20 countries 2000 to 2030: a modelling study
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Tiago++Cravo+Oliveira+Hashiguchi&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Cravo Oliveira Hashiguchi Tiago </a>, <a href="/search?value1=Driss++Ait+Ouakrim&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ait Ouakrim Driss </a>, <a href="/search?value1=Michael+Padget&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Padget Michael</a>, <a href="/search?value1=Alessandro+Cassini&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Cassini Alessandro</a>, <a href="/search?value1=Michele+Cecchini&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Cecchini Michele</a></span>. Resistance proportions for eight priority antibiotic-bacterium combinations in OECD, EU/EEA and G20 countries 2000 to 2030: a modelling study. <a href="/content/ecdc">Euro Surveill.</a> 2019;24(20):pii=1800445. <a href="https://doi.org/10.2807/1560-7917.ES.2019.24.20.1800445" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2019.24.20.1800445</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 10 Aug 2018;&nbsp;&nbsp; <span class="generated">Accepted</span>: 21 Mar 2019 </span> </p>
/content/10.2807/1560-7917.ES.2019.24.20.1800445
/content/10.2807/1560-7917.ES.2019.24.20.1800445
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error